Editorial
Expanding treatment options for metastatic gastric cancer
Abstract
Li et al. published a clinical study evaluating the efficacy and safety of Apatinib (a small-molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) versus placebo in the treatment of patients with gastric or gastroesophageal junction adenocarcinoma for whom at least two lines of prior chemotherapy had failed (1).
